Pharmacy Benefits Management

April 25, 2022

New Caplyta Dosage Strengths Approved

April 25, 2022 – Caplyta® (lumateperone) has received FDA approval for two new dosages strengths: 10.5mg capsules and 21mg capsules.
April 22, 2022

Pfizer Recalls Five Lots of Accupril

April 22, 2022 – Pfizer has recalled five lots of Accupril® (quinapril HCl) tablets due to the presence of a nitrosamine identified as above the established acceptable daily intake
April 21, 2022

Zerbaxa Now Indicated for Children

April 21, 2022 – Zerbaxa® (ceftolozane/tazobactam) has received an expanded indication to treat complicated intra-abdominal infections and complicated urinary tract infections